Difference between revisions of "Vemurafenib (Zelboraf)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| Line 21: | Line 21: | ||
==Also known as== | ==Also known as== | ||
| − | PLX4032, RG7204, | + | *'''Code names:''' PLX4032, RG7204, RO5185426 |
| + | *'''Brand name:''' Zelboraf | ||
==References== | ==References== | ||
| Line 27: | Line 28: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:BRAF inhibitors]] | [[Category:BRAF inhibitors]] | ||
| + | [[Category:MAP2K4 inhibitors]] | ||
| + | [[Category:MAP4K5 inhibitors]] | ||
| + | [[Category:ZAK inhibitors]] | ||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
Revision as of 19:51, 18 August 2017
General information
Class/mechanism: Tyrosine kinase inhibitor of some mutated forms of BRAF serine/threonine
kinase, including BRAF V600E. Also has been observed to inhibit other tyrosine kinases such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR. Certain BRAF mutations, such as V600E, result in constitutive activation of cell proliferation pathways and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
More drug information
History of changes in FDA indication
- 8/17/2011: Initial FDA approval "for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test."
- Limitation: "ZELBORAF is not recommended for use in patients with wild-type BRAF melanoma."
Also known as
- Code names: PLX4032, RG7204, RO5185426
- Brand name: Zelboraf